Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study
Hong Kong study using valsartan in IgA nephropathy (HKVIN): A double-blind, randomized, placebo-controlled study
复制标题
DOI：
10.1053/j.ajkd.2006.01.017
复制
发表时间：
2006-05-01
影响因子：
13.2
通讯作者：
Szeto, Cheuk Chun
中科院分区：
文献类型：
--
作者：
Li, Philip Kam-Tao;Leung, Chi Bon;Szeto, Cheuk Chun
背景既往研究表明，血管紧张素受体阻滞剂（ARB）治疗可减少慢性蛋白尿肾病患者的蛋白尿，并可能减缓肾功能下降的速度。我们进行了一项关于ARB缬沙坦治疗免疫球蛋白A（伊加）肾病患者的双盲、随机、安慰剂对照、多中心研究。研究方法：我们从6个中心招募了109名伊加肾病患者，他们有：（1）蛋白尿蛋白大于1 g/d，血清肌酐水平小于2.8 mg/dL，
Background Previous studies showed that angiotensin-receptor blocker (ARB) therapy decreased proteinuria and possibly slowed the rate of renal function decline in patients with chronic proteinuric nephropathies. We performed a double-blind, randomized, placebo-controlled, multicenter study on the ARB valsartan in the treatment of patients with immunoglobulin A (IgA) nephropathy. Methods: From 6 centers, we recruited 109 patients with IgA nephropathy who had either: (1) proteinuria with protein greater than 1 g/d and serum creatinine level less than 2.8 mg/dL (